What happened with VOGX today?
No read yet
Uses news and trading volume to explain the day’s move and how it relates to the market.
Stop guessing. Get the call, a three-month target price, the best and worst cases, and a source for every claim.
Vogenx Inc focuses most of its development resources on mizagliflozin for people who experience low blood sugar after weight-loss surgery, a condition called post-bariatric hypoglycemia. It is also developing this candidate for gastroparesis, which slows stomach emptying, and GIP-dependent Cushing’s syndrome. None of its candidates is approved for sale.
Investors and lenders, rather than medicine buyers, currently fund the business through equity and convertible debt. Vogenx needs substantial additional capital beyond its IPO proceeds to advance its drugs through late-stage trials and approval. Future product sales depend on successful development and regulatory approval; commercial uptake would also depend on insurers and government healthcare programs providing adequate coverage and reimbursement.
The central mizagliflozin program relies on rights licensed from Kissei Pharmaceutical Co., Ltd. These rights are exclusive outside Japan, Korea and Taiwan, and require Vogenx to pay Kissei development and regulatory milestones and royalties on eventual sales. Vogenx also relies on outside providers to conduct trials and manufacture its drug candidates.
The risk section is the longest, dullest part of the filing. This keeps only what can really hurt you: where it hits, how hard, when it plays out.
Every company claims an edge. Each one is checked against hard numbers like margins and returns: which hold, and which line gives way first.
Vogenx’s prospects depend on successful mizagliflozin trials and approval, with essential patent rights and know-how licensed from Kissei Pharmaceutical.
Amylyx Pharmaceuticals, Inc.’s avexitide competes directly with Vogenx’s mizagliflozin for treating patients with post-bariatric hypoglycemia; both drugs are still in development. Watch avexitide’s Phase 3 results, planned for 2026, for evidence of the competing treatment Vogenx could face before it earns any drug-sales revenue.
Vanda Pharmaceuticals Inc.’s tradipitant targets the same gastroparesis patients as Vogenx’s mizagliflozin, so its clinical and approval progress matters to Vogenx’s potential drug-sales market. Watch whether Vanda supplies the additional data the FDA sought to address safety and efficacy questions about tradipitant.
Fractyl Health, Inc.’s Revita procedure aims to prevent weight regain after patients stop GLP-1 therapy, competing for the weight-maintenance patients Vogenx hopes to treat with its preclinical drug VGX-2857. Watch the randomized six-month REMAIN-1 results expected in 2026: the study enrolled patients who had lost at least 15% of total body weight on GLP-1 therapy and wanted to stop without regaining weight.
Vanda Pharmaceuticals Inc. earningsVNDA
Vanda's report may update whether tradipitant can address FDA questions, which matters because it targets the same gastroparesis patients as Vogenx's mizagliflozin.
Look for any additional safety and efficacy data Vanda provides in response to the FDA's questions, and whether that brings regulatory progress. Evidence that addresses the questions would strengthen the prospect of tradipitant becoming a competing treatment for the patients Vogenx serves; inadequate or unfavorable evidence would weaken it, but would not show whether mizagliflozin works.
Amylyx Pharmaceuticals, Inc. earningsAMLX
Amylyx's report may update avexitide's Phase 3 results, testing a potential treatment for the same post-bariatric hypoglycemia patients Vogenx hopes to treat.
If Amylyx reports the Phase 3 results, look for evidence that avexitide treats post-bariatric hypoglycemia and whether Amylyx can move toward a regulatory application. Strong results with continued progress would make a competing treatment for Vogenx's target patients more plausible; weak results would lessen that evidence, but would not prove mizagliflozin works.
Fractyl Health, Inc. earningsGUTS
Fractyl's report may update whether its Revita procedure helps people keep weight off after GLP-1 therapy, a need Vogenx is also targeting with VGX-2857.
If Fractyl reports the six-month REMAIN-1 results, look at whether Revita reduced weight regain after patients stopped GLP-1 therapy. A clear benefit would support the procedure as another option for the patients targeted by VGX-2857; little improvement would weaken that case, but would not show whether VGX-2857 works.
Vogenx Inc earningsThis company
Vogenx has no approved drug for sale, so its report will show whether cash use is moving its PBH and gastroparesis programs forward.
Read the cash balance alongside cash used in operations, then compare research and development spending with any updates on the PBH and gastroparesis programs. Progress with cash use in line with the work would suggest the funding is advancing the drug candidates; faster cash depletion without corresponding progress would mean later development depends more heavily on new funding.
